To study the physiology of the high affinity vascular smooth muscle receptor for angiotensin II, we have characterized 125 I-angiotensin II binding sites in a participate fraction prepared from rat mesenteric arteries. 125 1-Angiotensin II binding was saturable at physiological concentrations of hormone, and was of high affinity. Scatchard analysis indicated a single class of binding sites with an equilibrium dissociation constant (Kd) of 0.91 ± 0.11 (SD) nM, and a total binding capacity of 53.7 ± 3.0 fmol/mg protein. Parallel studies with 3 H-angiotensin II yielded a similar Kj (1.18 ± 0.48 nM) and total binding capacity (56.8 ± 9.2 fmol/mg protein). m I-Angiotensin II associated with binding sites rapidly (ti/2 for association = 4 minutes at 37°C), and reversibly. Kinetic analysis of binding at 22°C by two independent methods yielded comparable values for both the association rate (4.0 and 6.8 x 10 5 /M per sec) and dissociation rate (3.2 and 3.8 x 10~Vsec) constants. Equilibrium dissociation constants calculated from kinetic analysis (0.56 and 0.80 nM) were in close agreement with that obtained from steady state Scatchard analysis. Analogues and antagonists of angiotensin II competed for binding in a potency series which exactly paralleled that observed for bioassay systems utilizing pressor response in vivo and vascular smooth muscle contraction in vitro. m I-Angiotensin II binding was stimulated 2to 3-fold in the presence of 1 nun divalent cations (Mn 2+ > Mg 2 * > Ca 2+ ) and reversibly inhibited by EDTA and EGTA. Dithiothreitol (5 mil), a sulfhydryl-reducing agent that has been reported to block vasoconstrictor response to angiotensin II, inhibited 125 I-angiotensin II binding by 45%. The present study defines specific angiotensin II binding sites in a muscular artery representative of the resistance vasculature. We conclude that these binding sites, unlike those previously described in conductancetype vessels (aorta), have a sufficiently high affinity to interact with physiological levels of hormone.
Identification and Characterization of the High Affinity Vascular Angiotensin II Receptor in Rat Mesenteric Artery
STEPHEN GUNTHER, MICHAEL A. GIMBRONE, JR., AND R. WAYNE ALEXANDER SUMMARY To study the physiology of the high affinity vascular smooth muscle receptor for angiotensin II, we have characterized 125 I-angiotensin II binding sites in a participate fraction prepared from rat mesenteric arteries. 125 1-Angiotensin II binding was saturable at physiological concentrations of hormone, and was of high affinity. Scatchard analysis indicated a single class of binding sites with an equilibrium dissociation constant (Kd) of 0.91 ± 0.11 (SD) nM, and a total binding capacity of 53.7 ± 3.0 fmol/mg protein. Parallel studies with 3 H-angiotensin II yielded a similar Kj (1.18 ± 0.48 nM) and total binding capacity (56.8 ± 9.2 fmol/mg protein). m I-Angiotensin II associated with binding sites rapidly (ti/2 for association = 4 minutes at 37°C), and reversibly. Kinetic analysis of binding at 22°C by two independent methods yielded comparable values for both the association rate (4.0 and 6.8 x 10 5 /M per sec) and dissociation rate (3.2 and 3.8 x 10~Vsec) constants. Equilibrium dissociation constants calculated from kinetic analysis (0.56 and 0.80 nM) were in close agreement with that obtained from steady state Scatchard analysis. Analogues and antagonists of angiotensin II competed for binding in a potency series which exactly paralleled that observed for bioassay systems utilizing pressor response in vivo and vascular smooth muscle contraction in vitro. m I-Angiotensin II binding was stimulated 2to 3-fold in the presence of 1 nun divalent cations (Mn 2+ > Mg 2 * > Ca 2+ ) and reversibly inhibited by EDTA and EGTA. Dithiothreitol (5 mil), a sulfhydryl-reducing agent that has been reported to block vasoconstrictor response to angiotensin II, inhibited 125 I-angiotensin II binding by 45%. The present study defines specific angiotensin II binding sites in a muscular artery representative of the resistance vasculature. We conclude that these binding sites, unlike those previously described in conductancetype vessels (aorta), have a sufficiently high affinity to interact with physiological levels of hormone. Circ Res 47; ANGIOTENSIN II, one of the most potent vasoconstrictor substances known, normally contributes to the maintenance of blood pressure (Haber et al., 1975) , and may play an important role in the pathogenesis of hypertension (Williams and Dluhy, 1977) . Peripheral vascular resistance is influenced not only by circulating plasma renin activity and angiotensin II levels, but also by alterations in the sensitivity to angiotensin II of vascular smooth muscle. Vascular responsiveness to angiotensin II varies during changes in sodium and potassium balance in several species, including man (Reid and Laragh, 1965; Hollenberg et al., 1975) , and is increased early in the development of experimental hypertension in animals (Collis and Alps, 1975) and in some patients with essential hypertension (Kisch et al., 1976) . It has been hypothesized that changes in the angiotensin II receptors of vascular smooth muscle may contribute to such altered vascular sensitivity. For example, the diminished response to angiotensin II observed during salt deprivation has been attributed to prior occupancy of receptors by elevated levels of endogenous angiotensin II (Thurston and Laragh, 1975) , or to a decrease in receptor number or affinity (Brunner et al., 1972) . To date, none of these hypotheses has been tested directly using ligand-binding assays for the vascular angiotensin II receptor. High-affinity receptors for angiotensin II previously have been characterized in nonvascular tissues, including adrenal cortex (Glossmann et al., 1974) , uterine smooth muscle , renal glomeruli (Sraer et al., 1974) , and brain (Bennett and Snyder, 1976) . However the angiotensin II receptor involved in controlling vascular resistance has been difficult to identify. Such a receptor should have the following properties: (1) sufficiently high affinity to allow interaction with circulating levels of angiotensin II; (2) specificity for angiotensin II and its analogues which parallels that observed in pharmacological studies; and (3) localization in vessels that are physiologically similar to the resistance vasculature. Angiotensin II binding sites have been identified in intact rabbit aorta (Lin and Good-friend, 1970) and in aortic microsomal preparations from rabbit (Baudouin et al., 1972; Devynck et al., 1973) and guinea pig (LeMorvan and Palaic, 1975) . However, these binding sites probably are not representative of the vascular angiotensin II receptors which participate in the regulation of blood pressure. Their affinity for angiotensin II is low (equilibrium dissociation constants, or Kd, = 13-55 nM) relative to the circulating levels of the hormone (0.01-0.10 nM in most species) (Boucher et al., 1977) . Moreover, physiological responses to angiotensin II in the aorta, a fibroelastic, conductive-type vessel, differ from those in muscular, resistance-type vessels (Bohr and Uchida, 1967; Altura and Altura, 1970) . Direct characterization of the high-affinity angiotensin II receptor in muscular, resistance-type arteries has not been reported.
As an initial approach to studying the angiotensin II receptor of muscular arteries, we have defined the biochemical characteristics of 125 I-angiotensin II binding sites in a particulate fraction of rat mesenteric arteries, vessels highly sensitive to angiotensin II (Bohr and Uchida, 1967) . The affinity, saturability, and specificity of these binding sites suggest they are representative of vascular smooth muscle receptors which mediate the effects of angiotensin 11 on blood pressure.
Methods

125
I-angiotensin II (specific activity, 1000-1600 Ci/mmol) and 3 H-angiotensin II (specific activity, 25.6 Ci/mmol) were obtained from New England Nulear. Radiochemical purity, verified by thin layer chromatography, was greater than 98%. Both ligands were stored at -20°C. Aliquots were used only once after thawing. The (l-7)heptapeptide and (3-8)hexapeptide derivatives of angiotensin II were kindly provided by Dr. E. Haber, and the [Sari,Ala«] and [des-Aspi,Alag] analogues of angiotensin II by Dr. N. Hollenberg. All other peptides were obtained from Peninsula Labs, Inc. Chymotrypsin-inactivated trypsin (L-l-tosylamide-2-phenylether-chloromethyl ketone-treated trypsin) and pancreatic trypsin inhibitor were obtained from Worthington Biochemical Corp. All other chemicals were obtained from Sigma Chemical Corp.
Male Sprague-Dawley rats (300-325 g) were obtained from Charles River Breeding Labs and were maintained on standard laboratory chow. Crude particulate fractions of mesenteric arteries were prepared by modifications of the method of Wei et al. (1976) . Briefly, the small intestines and mesenteric vascular arcades were removed en bloc from 12 rats and placed immediately in ice-cold phosphate-buffered saline (pH 7.4). The intestine, mesenteric veins, and fat were removed by blunt dissection, and the remaining Heal, jejunal, and superior mesenteric arteries and their branches were transferred to a 32 X 130 mm Potter-Elvehjem glass homogenizer (Wheaton Ind.) containing ice-cold 0.25 M sucrose. Loosely adherent fat was removed with three strokes of a specially machined (0.016" clearance) tapered, smooth Teflon pestle. The cleaned arteries were homogenized in fresh ice-cold 0.25 M sucrose with a Brinkman Polytron (setting 8, 2 X 10 seconds) and the resulting suspension centrifuged at 1500 g for 10 minutes at 4°C. The supernatant was carefully decanted and recentrifuged as above. The final supernatant was then centrifuged at 104,000 g for 30 minutes at 4°C. The pellet (3.5-4.0 mg protein) was resuspended in 3.8 ml "assay buffer" (50 mM Tris-HCl, 5 mM MgCl 2 , 0.25% bovine serum albumin, pH 7.2 at 22°C).
Binding assays were performed by incubating portions of freshly prepared particulate fraction (80 to 100 fig protein) with varying concentrations of radionuclide-labeled angiotensin II in 12 X 75 mm polystyrene tubes (Falcon 2052) in a final volume of 0.10 to 0.20 ml assay buffer. After incubation in a gyratory metabolic shaker for periods up to 90 minutes (at 22°C, unless otherwise specified), 3 ml of ice-cold 0.9% NaCl were added to each assay tube, and the bound and free radioactivity rapidly separated by filtration through glass-fiber filters (Whatman GF/C) pre-wetted with 1 ml of assay buffer. The incubation tubes and filter wells were rinsed with two additional 3-ml portions of ice-cold 0.9% NaCl. The filters were dried in room air, and trapped radioactivity was determined by counting in a y counter (Searle) with a 70% counting efficiency or, in the case of 3 H-angiotensin II, in a Beckman liquid scintillation counter at 42% efficiency. Assays were performed in duplicate or triplicate for each experimental point. All data presented represent specific binding, defined as that displaceable by 1 fM unlabeled angiotensin II added to the incubation mixture. Filter banks determined in the absence of tissue averaged 0.20 ± 0.05% of total radioactivity.
Degradation of I25 I-angiotensin II during the binding assays was assessed by thin layer chromatography. Particulate fraction protein (1 mg/ml) was incubated with 125 I-angiotensin II (1 nM) at 22°C for 60 minutes, then centrifuged at 20,000 g for 30 min at 4°C. The supernatant was saved on ice; the pellet was washed once in cold assay buffer, resuspended in cold 0.05 M acetic acid, and incubated on ice for 30 minutes. Following recentrifugation, the acid eluate (neutralized with 0.1 M NaOH) was chromatographed, along with the original supernatant (incubation medium) and authentic 125 I-angiotensin II on thin layer cellulose plates (Eastman 6065), and developed with tert-butyl alcohol: 3% NH 3 (105:35) as solvent. Developed chromatograms were scanned for radioactivity (Packard radiochromatogram scanner, model 7021).
The trypsin sensitivity of particulate fraction 125 Iangiotensin II binding sites was measured by preincubating particulate fraction (100 jug protein in 100 jul assay buffer minus albumin and MgCl 2 ) for 3 minutes at 22°C, then adding L-l-tosylamide-2- VOL. 47, No. 2, AUGUST 1980 phenylether-chloromethyl ketone-treated trypsin (20 fig in 20 fil). After 10 minutes of incubation at 22°C, pancreatic trypsin inhibitor (25 fig in 20 jul) was added, and 2 minutes were allowed for trypsin inactivation. Albumin (final concentration, 0.25%) and 125 I-angiotensin II (final concentration 0.3 nM) then were added for a final assay volume of 200 yu. 1, and binding was determined at 60 minutes, as described above. For control purposes, particulate fractions also were treated with assay buffer alone, and with trypsin pre-mixed with pancreatic trypsin inhibitor.
Statistical analysis of binding constants was performed by Student's £-test, with the null hypothesis being rejected when P < 0.05. All data are presented as mean ±SD.
Results
Binding Assay 125 I-angiontensin II binding to particulate fractions was linear with protein concentration over the range of 10 to 200 /xg ( Fig. 1 ). Specific binding for all experiments averaged 91 ± 2% of total binding, and under standard assay conditions, averaged 0.2 to 2.5% of total radioactivity present. Thin layer chromatography of both the 125 I-angiotensin II bound to the particulate fraction and the 125 I-angiotensin II remaining unbound in the incubation medium resulted in patterns identical to that observed for intact 125 I-angiontensin II (Fig. 2) . Thus, there appeared to be no appreciable degradation of the angiotensin II ligand by the vascular preparation under the assay conditions employed. To provide additional evidence that the binding site identified by 125 I-angiotensin II was the physiological angiotensin II receptor, similar experiments were performed using 3 H-angiotensin II, a ligand maintaining full biological potency (Morgat et al., 1970) . The K d (1.18 ± 0.48 nM, n = 4) and binding 60 TIME (minutes) FIGURE 4 Effect of temperature on 12S I-angiotensin II binding to rat mesenteric artery particulate fraction. 125 I-angiotensin II (0.5 nM) was incubated for varying times with 100 ng protein at the temperatures indicated. Results for 22° C are the mean of three separate determinations. Results for 5°C and 37° C are the mean of two separate determinations. capacity (56.8 ± 9.2 fmol/mg protein) did not differ significantly from those observed for 125 I-angiotensin II (P > 0.1 in each instance).
Kinetics of 125 1-Angiotensin II Binding to Particulate Fractions
125
I-Angiotensin II binding to rat mesenteric artery particulate fractions was temperature dependent ( Fig. 4) . At 22°C, steady state was reached by approximately 40 minutes and remained stable for an additional 60 minutes. The association rate constant at 22 °C, estimated by fitting the binding data to the second order rate equation (Fig. 5 ) was 4.0 X 10 5 /M per sec. The dissociation rate constant at 22°C, determined by fitting the binding data from the experiments described in Figure 5 to the pseudo- . Unlabeled angiotensin II (10 fil, final concentration 1 fiM) was then added and the amount of bound 12S 1'-angiotensin II at varying times was determined as described under "Methods." The dissociation rate constant was estimated by fitting the binding data to the pseudo-first order rate equation. Results are the mean of three separate determinations. VOL. 47, No. 2, AUGUST 1980 first order rate equation, was 3.2 X 10 4 /sec. The Ka at 22°C, calculated from the ratio of the rate constant for dissociation to the rate constant for association, was 0.80 nM, in good agreement with the value obtained from steady state experiments.
Association and dissociation rate constants also were estimated by a method free of the assumptions made in the fitting of binding data to the second order and pseudo-first order rate equation (see Appendix for details of the calculation). As depicted in Figure 6 , the resulting association rate constant was 6.8 X 10 5 /M per sec and the dissociation rate constant was 3.8 X 10" 4 /sec. The Kd calculated from these values is 0.56 nM.
Specificity of 125 I-Angiotensin II Binding to Participate Fractions
The potency of angiotensin II analogues and antagonists, as well as the unrelated peptides bradykinin and substance P, in competing with 125 I-angiotensin II for binding sites in rat mesenteric artery particulate fractions is depicted in Figure 7 fold less than that of [Ile 5 ]angiotensin II, whereas bradykinin and substance P were essentially devoid of activity.
Other Characteristics of 125 1-Angiotensin II Binding to Particulate Fractions
Binding of 125 I-angiotensin II was increased in the presence of divalent cations (Ca 2+ , Mg 2+ , and Mn 2+ in increasing order of potency), and inhibited by both EDTA and EGTA (Fig. 8) . The inhibition by EDTA and EGTA could be reversed by the addition of equimolar amounts of Ca 2+ . Binding was inhibited by 45% by the addition of 5 mM dithiothreitol (from 11.0 ± 1.5 to 6.0 ± 2.2 fmol/mg, at an 125 I-angiotensin II concentration of 0.3 nM), but neither total binding nor kinetics were altered by 100 mM NaCl or KC1, 10~5 M glucagon, or 10" 4 M GTP. Pretreatment of particulate fractions with trypsin reduced 125 I-angiotensin II binding to 7% of control values (from 0.57 ± 0.05 to 0.05 ± 0.02 fmol/ assay tube, n = 3), suggesting that a protein component forms an integral part of the binding site complex. Binding at pH 6.5 or 8.0 was only 60% of the maximum observed at pH 7.2. Particulate fractions subjected to a single freeze-thaw cycle (24 hours at -20°C) bound only 40% as much 125 Iangiotensin II as control (5.3 ± 0.3 vs. 14.0 ± 0.8 fmol/mg protein, respectively, at an 125 I-angiotensin II concentration of 0.3 nM, n = 3). However, the affinity of the binding site, estimated by the angiotensin II concentration producing 50% displacement of binding (as depicted in Fig. 7) , was only minimally altered (from 3.0 ± 0.3 to 5.0 ± 0.5 nM). Effect of divalent cations, EDTA and EGTA, on binding of 125 1-angiotensin II to rat mesenteric artery particulate fraction. 12S 1-angiotensin II (0.3 nM) was incubated for 90 minutes at 22°C with 100 fxg protein as described under "Methods," except that 5 m.M MgCli was omitted from the incubation mixture. Cations (chloride salt), Na 2 EDTA, and Na 2 EGTA were added at the specified concentrations. Results are the mean of three separate determinations.
Discussion
The 125 I-angiotensin II binding sites demonstrated in the rat mesenteric artery particulate fraction in this study have the characteristics expected of receptors mediating the effects of angiotensin II on peripheral vascular resistance. Specific binding is saturable, of high affinity and low capacity (Fig.  3) . 125 1-Angiotensin II binds rapidly and reversibly at 22°C (Figs. 4 and 5) . The specificity of angiotensin II and its analogues in competing for binding sites in the particulate fraction (Fig. 7) exactly parallels their specificity in interacting with the vascular angiotensin II receptor in pharmacological preparations (Regoli et al., 1974) . These angiotensin II binding sites thus are similar in their high affinity and specificity to angiotensin II receptors previously described in nonvascular tissue (Glossmann et al., 1974; Sraer et al., 1974; Bennett and Snyder, 1976) .
The affinity of the 125 I-angiotensin II binding sites in the rat mesenteric artery particulate fraction (Kd = 0.91 ni«) is sufficiently high to permit interaction with circulating levels of angiotensin II, as measured in the rat (=0.05-0.60 nM) under var-ious physiological conditions (Powell-Jackson and MacGregor, 1976) . This high affinity contrasts with the considerably lower affinities (Kd = 13-55 nM) reported for angiotensin II binding sites in the aorta (Baudouin et al., 1972; Devynck et al., 1973; Le-Morvan and Palaic, 1975) . In the latter studies, the inability to detect specific binding at physiological concentrations of radioactive angiotensin II (<1 nM) raises questions as to the relevance of such binding sites to the problem of defining the physiology of angiotensin II receptors controlling vascular resistance.
In the current study, association and dissociation rate constants estimated by standard kinetic analysis of binding data (F,ig. 5) resulted in a calculated Kd of 0.80 nM, which agrees well with that obtained by steady state Scatchard analysis. However, certain assumptions made in the fitting of binding data to second order and pseudo-first order rate equations make the calculations of rate constants by this method subject to several potential errors: (1) dissociation of bound hormone from the receptor complex is assumed to be negligible during the early, "linear" phase of association; (2) the value of N o (= concentration of binding sites) is assumed to be known as accurately as the directly measured H o (= initial free hormone concentration), when in fact No is indirectly estimated from the Scatchard plot; and (3) if dissociation of bound hormone is not complete (i.e., reaches a non-zero asymptote), the estimated value for the dissociation rate constant will be artifactually low (Rodbard, 1973) . Often, practical considerations, as in the present study with a relatively low dissociation rate constant (ti /2 = 36 minutes at 22°C), do not permit a zero asymptote for dissociation to be verified experimentally. For these reasons, the integrated rate equation method described in Figure 6 and the Appendix was chosen to estimate independently the calculated rate constants. The only assumptions of this method are directly verifiable-that H t = Ho for all times (t), and that binding reflects a reversible, bimolecular reaction with a single class of binding sites (i.e., no site-site interaction or cooperativity). Since rat mesenteric artery particulate fractions in all experiments bound less than 3% of total radioactivity initially present, the former assumption appears justified. The validity of the assumed model for the angiotensin II binding site in our system is supported by the close approximation of the calculated Kd (0.56 nM) with that obtained from Scatchard analysis. Both the kinetic and steady state data indicate a single class of binding sites without cooperativity, consistent with pharmacological observations suggesting that angiotensin II interacts with vascular receptors according to the law of mass action (Rioux et al., 1973) .
In previous studies of high-affinity angiotensin II binding sites in nonvascular tissue including rat adrenal (Glossmann et al., 1974) , renal glomeruli (Sraer et al., 1974) , and bovine brain (Bennett and VOL. 47, No. 2, AUGUST 1980 Snyder, 1976) , appreciable metabolism of labeled angiotensin II was apparent. This degradation necessitated the addition of EDTA, unrelated peptides (ACTH or glucagon), protease inhibitors (phenylmethylsulfonylfluoride), and/or disulfidereducing agents (dithiothreitol). Although these substances inhibited degradation of labeled angiotensin II, their effects on the receptor itself are unknown. Under our assay conditions, we were unable to detect any degradation of 125 I-angiotensin II by the rat mesenteric artery particulate fraction, even after 60 minutes of incubation at 22°C (Fig.  2) . Furthermore, the addition of 10 /XM glucagon or 1 jiiM phenylmethylsulfonylfluoride did not increase specific binding (data not shown), whereas 5 mM dithiothreitol actually reduced binding by 45%. Dithiothreitol has been reported to inhibit specifically the contractile response of isolated vascular strips to angiotensin II, whereas contractions induced by norepinephrine, serotonin, and histamine are either unaffected or potentiated (Fleisch et al., 1973) . Our data thus are consistent with the original suggestion by these authors that disulfide bonds are necessary for the functional integrity of the vascular angiotensin II receptor.
The divalent cations Mn 2+ , Mg 2+ , and Ca 2+ enhance binding of l25 I-angiotensin II to the rat mesenteric artery particulate fraction, whereas the chelators, EDTA and EGTA, reversibly inhibited binding ( Fig. 8 ). Similar effects have been observed for angiotensin II binding to rat renal glomeruli (Blanc et al., 1978) , whereas Ca 2+ and Mg 2 * decreased angiotensin II binding in rabbit aorta . The significance of these differences is unclear, but they suggest that angiotensin II receptors may vary in their biochemical nature from tissue to tissue and even from blood vessel to blood vessel. The enhancement of angiotensin II binding by Mn 2+ and Mg 2+ is somewhat surprising, as these cations tend to depress the vasoconstrictor response to angiotensin II in vitro (Bohr, 1974) . However, it is possible they also affect events other than hormone-receptor interactions.
Physiological responses to angiotensin II are well-known to vary in a tissue-specific manner. It is likely that such variations reflect inherent differences in angiotensin II receptors. For example, although angiotensin II is more potent than [des-Aspi ]angiotensin II (A III) in terms of pressor response (Regoli et al., 1974) , the two hormones appear equipotent in terms of eliciting aldosterone production by adrenal cells (Blair-West et al., 1971; Chiu and Peach, 1974) . Corresponding differences in receptor affinity for the two peptides have been observed using ligand-binding assays in adrenal cortex (A III = A II) (Glossmann et al., 1974; Devynck et al., 1977) and in rat mesenteric artery (A II > A III, Fig. 7) . Recent pharmacological evidence suggests that angiotensin II receptor heterogeneity exists even among different arterial vessels (Caldicott and Hollenberg, 1979) . These data emphasize the need for studying angiotensin II receptors in vascular beds contributing importantly to peripheral resistance.
All previous direct studies of vascular angiotensin II receptors have been limited to the aorta Baudouin et al., 1972; LeMorvan and Palaic, 1975) . The difficulties in extrapolating data from this fibroelastic conductance vessel to muscular resistance vessels, which are primarily involved in the vascular responsiveness to angiotensin II, have been discussed . In addition to obvious structural differences, the aorta in many species is functionally not representative of the resistance vasculature. For example, tachyphylaxis to low levels of exogenous angiotensin II is not a prominent feature of the dog (Khairallah et al., 1966) , rabbit (Altura and Altura, 1970) , or guinea pig (Palaic and LeMorvan, 1971) aorta. In contrast, the pressor response to angiotensin II in these and other species exhibits marked tachyphylaxis (Stewart, 1974) . The mesenteric arterial bed, on the other hand, is a significant determinant of systemic vascular resistance, and, like the pressor response in the intact animal, demonstrates tachyphylaxis to angiotensin II in both perfused preparations and helical vascular strips (Bohr and Uchida, 1967; Collis and Alps, 1975) . Thus, the mesenteric artery angiotensin II receptor appears to be more representative of those receptors modulating peripheral resistance than the aortic receptor. Moreover, as this study demonstrates, sufficient tissue to conduct binding studies can be obtained easily from the rat, a species in which both normal vascular homeostasis, as well as spontaneous and induced hypertension, have been studied extensively.
Radioiodinated I25 I-angiotensin II has been used to identify high affinity receptors in several nonvascular tissues (Glossman et al., 1974; Sraer et al., 1976; Bennett and Snyder, 1976) . In the case of vascular angiotensin II receptor, where low binding capacity and relatively small amounts of smooth muscle membrane material are important limitations, the higher specific activity of 125 I-angiotensin II offers an advantage over the 3 H-or 14 C-angiotensin II preparations previously used (Baudouin et al., 1972; Devynck et al., 1973; LeMorvan and Palaic, 1975) . Tritium-labeled angiotensin II was selected originally because it maintained full biological potency (Morgat et al., 1970) , in contrast to 125 I-angiotensin II, which has only one-third the pressor activity of the native hormone . However, direct comparison of 125 I-angiotensin II and 3 H-angiotensin II binding characteristics in the mesenteric artery in the present study, as well as in previously published studies of bovine adrenal cortex (Glossman et al., 1974) , suggests that these two radioligands interact with angiotensin II receptors in an essentially similar fashion.
In conclusion, the present study defines biochem-ical characteristics of 125 I-angiotensin II binding sites in a muscular artery representative of the resistance vasculature. These binding sites, unlike those in aorta, interact with physiological concentrations of hormone, and exhibit the properties expected of an angiotensin II receptor which modulates vasculature resistance. The ability to characterize and quantify such receptors should facilitate the study of their physiological regulation in normal animals and their pathological alterations in hypertensive models.
Appendix
Derivation of Association and Dissociation Rate Constants from Kinetic Data Using Two Concentrations of Ligand
For the reaction of hormone (H) binding reversibly with a single class of receptor sites (R) to form a receptor-bound hormone complex (B) when the initial free hormone concentration, Ho :» Ro, so that Ho = H t for all times t, the rate of change of the concentration of bound hormone is approximated by: can be solved to yield:
-o k l = > a n d k " 1 S Ho -SHo response to increases in systolic pressure caused by intravenous injections of phenylephrine resulted from an increase in cardiac vagal tone. Phenylephrine has no direct cardiac effect (Varma et al., 1960) . However, in the dog, the sheep, and fetal lamb, when arterial pressure was increased by intravenous injection of angiotensin II there was no progressive increase in pulse interval as systolic pressure rose (Ismay et al., 1979; Lumbers et al., 1979) . In both species this lack of cardiac slowing seen with acute transient increases in systolic pressure caused by angiotensin II was due to a central inhibitory action
